Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cholic Acid

FDA-approved product (capsule, oral), marketed as Cholbam.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cholic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormality of the gastrointestinal tract
  • Inborn errors of metabolism
  • Liver disease
  • Peroxisomal disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bile acids and derivatives
FDA pharmacologic class
Bile Acid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cholic Acid in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cholic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients

    NCT03844100 · start 2019-11-01

    Registered record
    Registry ID
    NCT03844100
    Conditions
    Dyspepsia; Biliary Dysplasia
    Interventions
    efficacy and safety of CNU® Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-11-01
    Completion
    2021-08-04
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyspepsia; Biliary Dysplasia
    Interventionefficacy and safety of CNU® Capsule
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Cholate Clearance in Fontans

    NCT03726229 · start 2019-05-01

    Registered record
    Registry ID
    NCT03726229
    Conditions
    Fontan Procedure
    Interventions
    Cholate assay
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-01
    Completion
    2022-05-25
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFontan Procedure
    InterventionCholate assay
    PhaseNot recorded
    Registry statusCompleted

  • Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

    NCT03602976 · start 2018-08-20

    Registered record
    Registry ID
    NCT03602976
    Conditions
    Hepatic Sarcoidosis, Elevated Alkaline Phosphatase
    Interventions
    Ursodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-08-20
    Completion
    2022-01-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Sarcoidosis, Elevated Alkaline Phosphatase
    InterventionUrsodeoxycholic Acid
    PhasePhase 2
    Registry statusTerminated

  • Kybella With Triamcinolone

    NCT03361176 · start 2018-03-26

    Registered record
    Registry ID
    NCT03361176
    Conditions
    Adiposity
    Interventions
    Injectable sodium deoxycholate; Injectable sodium deoxycholate with Triamcinolone acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-26
    Completion
    2018-12-18
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdiposity
    InterventionInjectable sodium deoxycholate; Injectable sodium deoxycholate with Triamcinolone acetate
    PhasePhase 4
    Registry statusCompleted

  • Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives

    NCT04281082 · start 2018-01-01

    Registered record
    Registry ID
    NCT04281082
    Conditions
    Cholestasis of Pregnancy
    Interventions
    ursofalk
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2022-01-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholestasis of Pregnancy
    Interventionursofalk
    PhaseNot recorded
    Registry statusUnknown

  • The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology

    NCT03294941 · start 2017-12-08

    Registered record
    Registry ID
    NCT03294941
    Conditions
    NASH - Nonalcoholic Steatohepatitis
    Interventions
    HepQuant SHUNT Liver Diagnostic Kit
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-12-08
    Completion
    2019-09-11
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNASH - Nonalcoholic Steatohepatitis
    InterventionHepQuant SHUNT Liver Diagnostic Kit
    PhasePhase 2
    Registry statusTerminated

  • Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy

    NCT03168555 · start 2017-06-22

    Registered record
    Registry ID
    NCT03168555
    Conditions
    Bile Acid Malabsorption; Cholelithiasis
    Interventions
    chenodeoxycholic acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-06-22
    Completion
    2019-05-15
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBile Acid Malabsorption; Cholelithiasis
    Interventionchenodeoxycholic acid
    PhasePhase 4
    Registry statusCompleted

  • A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting Conditions

    NCT03512808 · start 2017-06-01

    Registered record
    Registry ID
    NCT03512808
    Conditions
    Healthy
    Interventions
    Ursodiol 500 MG; Urso Forte 500Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-01
    Completion
    2017-07-31
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionUrsodiol 500 MG; Urso Forte 500Mg Tablet
    PhasePhase 1
    Registry statusCompleted

  • Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment

    NCT02841306 · start 2016-07

    Registered record
    Registry ID
    NCT02841306
    Conditions
    Rhegmatogenous Retinal Detachment
    Interventions
    Ursodeoxycholic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-09
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhegmatogenous Retinal Detachment
    InterventionUrsodeoxycholic Acid
    PhasePhase 1
    Registry statusCompleted

  • Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR

    NCT03659058 · start 2016-03-02

    Registered record
    Registry ID
    NCT03659058
    Conditions
    Fibrosis, Liver
    Interventions
    silymarin; Ursodeoxycholic Acid; Antioxidants; Colchicine; FOLLOW UP
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-03-02
    Completion
    2018-08-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFibrosis, Liver
    Interventionsilymarin; Ursodeoxycholic Acid; Antioxidants; Colchicine +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

    NCT02684591 · start 2016-01

    Registered record
    Registry ID
    NCT02684591
    Conditions
    Nonalcoholic Fatty Liver Disease; HIV
    Interventions
    Aramchol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-01
    Completion
    2018-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonalcoholic Fatty Liver Disease; HIV
    InterventionAramchol; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA

    NCT02965911 · start 2016-01

    Registered record
    Registry ID
    NCT02965911
    Conditions
    Primary Biliary Cirrhosis
    Interventions
    Fenofibrate; UDCA
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2016-01
    Completion
    2021-09-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Biliary Cirrhosis
    InterventionFenofibrate; UDCA
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery

    NCT02319629 · start 2014-12

    Registered record
    Registry ID
    NCT02319629
    Conditions
    Morbid Obesity
    Interventions
    URSODIOL; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2018-12
    Enrolment
    266

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorbid Obesity
    InterventionURSODIOL; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.

    NCT02418130 · start 2014-10

    Registered record
    Registry ID
    NCT02418130
    Conditions
    Fatigue
    Interventions
    Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-03
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFatigue
    InterventionUrsodeoxycholic acid, taurine, ginsenoside, thiamine, inositol; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

    NCT02123134 · start 2014-04

    Registered record
    Registry ID
    NCT02123134
    Conditions
    Moderate to Severe Convexity of Submental Fat; Safety; Efficacy
    Interventions
    ATX-101; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-09
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate to Severe Convexity of Submental Fat; Safety; Efficacy
    InterventionATX-101; Placebo
    PhasePhase 3
    Registry statusCompleted